Network identification

PURI

https://redirect.ema.europa.eu/resource/4199

Network ID

4199

Network name and Acronym

PROTECT

Network countries

Belgium
Denmark
France
Germany
Italy
Netherlands
Poland
Spain
Sweden
Switzerland
United Kingdom

Network website

ENCePP partner

No
Network description
[PROJECT NOW CLOSED] PROTECT was a public-private European project funded by the Innovative Medicines Initiative Joint Undertaking. It comprised a 5 year research programme to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. The European Medicines Agency was the coordinator and Glaxo Smith Kline was the deputy coordinator of this multi-national consortium of 31 partners. The goal was to strengthen the monitoring of the benefit/risk of medicines in Europe. This was achieved by developing a set of innovative tools and methods to improve the early detection of safety signals, enhance direct data collection from consumers and provide for a continuous benefit/risk monitoring of medicines. In addition, a methodological framework of pharmacoepidemiology studies was developed aiming at increasing the usefulness and reliability of these studies for benefit/risk assessment. All methods were tested to demonstrate their usefulness and applicability. This network was an ENCePP partner.
Network details
Network primary therapeutic area:
Other
Network funding:
EU institutional research programme

Contact

Institutions that are part of this network